News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
859,405 Results
Type
Article (87414)
Company Profile (739)
Press Release (771234)
Multimedia
Podcasts (197)
Webinars (28)
Section
Business (232804)
Career Advice (4143)
Deals (39874)
Drug Delivery (144)
Drug Development (91179)
Employer Resources (205)
FDA (18254)
Job Trends (17422)
News (396899)
Policy (39843)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3002)
Academic (1)
Accelerated approval (31)
Adcomms (30)
Allergies (120)
Alliances (56816)
ALS (154)
Alzheimer's disease (1753)
Antibody-drug conjugate (ADC) (313)
Approvals (18383)
Artificial intelligence (471)
Autoimmune disease (156)
Automation (31)
Bankruptcy (403)
Best Places to Work (12512)
BIOSECURE Act (23)
Biosimilars (204)
Biotechnology (457)
Bladder cancer (145)
Brain cancer (54)
Breast cancer (548)
Cancer (4343)
Cardiovascular disease (312)
Career advice (3568)
Career pathing (41)
CAR-T (290)
CDC (36)
Celiac Disease (2)
Cell therapy (763)
Cervical cancer (29)
Clinical research (76167)
Collaboration (1625)
Company closure (4)
Compensation (1004)
Complete response letters (64)
COVID-19 (2932)
CRISPR (85)
C-suite (743)
Cystic fibrosis (143)
Data (5478)
Decentralized trials (2)
Denatured (73)
Depression (116)
Diabetes (348)
Diagnostics (7001)
Digital health (25)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (255)
Drug pricing (163)
Drug shortages (19)
Duchenne muscular dystrophy (201)
Earnings (98169)
Editorial (57)
Employer branding (25)
Employer resources (173)
Events (132965)
Executive appointments (845)
FDA (20685)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (24)
Funding (1302)
Gene editing (184)
Generative AI (46)
Gene therapy (601)
GLP-1 (938)
Government (5323)
Grass and pollen (4)
Guidances (288)
Healthcare (20785)
HIV (43)
Huntington's disease (46)
IgA nephropathy (79)
Immunology and inflammation (267)
Immuno-oncology (58)
Indications (81)
Infectious disease (3152)
Inflammatory bowel disease (203)
Inflation Reduction Act (14)
Influenza (96)
Intellectual property (210)
Interviews (816)
IPO (17877)
IRA (45)
Job creations (5198)
Job search strategy (2866)
JPM (66)
Kidney cancer (16)
Labor market (92)
Layoffs (639)
Leadership (37)
Legal (10100)
Liver cancer (88)
Longevity (13)
Lung cancer (584)
Lymphoma (333)
Machine learning (42)
Management (66)
Manufacturing (721)
MASH (159)
Medical device (14495)
Medtech (14528)
Mergers & acquisitions (22794)
Metabolic disorders (1077)
Multiple sclerosis (152)
NASH (22)
Neurodegenerative disease (330)
Neuropsychiatric disorders (79)
Neuroscience (2906)
Neurotech (1)
NextGen: Class of 2026 (7686)
Non-profit (5080)
Now hiring (65)
Obesity (530)
Opinion (325)
Ovarian cancer (155)
Pain (163)
Pancreatic cancer (183)
Parkinson's disease (262)
Partnered (34)
Patents (416)
Patient recruitment (418)
Peanut (56)
People (66341)
Pharmaceutical (133)
Pharmacy benefit managers (21)
Phase 1 (23618)
Phase 2 (33145)
Phase 3 (24831)
Pipeline (4368)
Policy (283)
Postmarket research (3544)
Preclinical (10598)
Press Release (72)
Prostate cancer (210)
Psychedelics (51)
Radiopharmaceuticals (283)
Rare diseases (803)
Real estate (7422)
Recruiting (80)
Regulatory (28289)
Reports (66)
Research institute (2696)
Resumes & cover letters (651)
Rett syndrome (21)
RNA editing (21)
RSV (63)
Schizophrenia (139)
Series A (226)
Series B (164)
Service/supplier (25)
Sickle cell disease (86)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (4323)
State (2)
Stomach cancer (15)
Supply chain (77)
Tariffs (76)
The Weekly (122)
Vaccines (1001)
Venture capital (91)
Weight loss (339)
Women's health (72)
Worklife (22)
Date
Last 7 days (479)
Last 30 days (1690)
Last 365 days (25884)
2026 (2443)
2025 (26229)
2024 (34415)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1280)
Alabama (85)
Alaska (6)
Arizona (306)
Arkansas (8)
Asia (51153)
Australia (9008)
California (9928)
Canada (2536)
China (1063)
Colorado (319)
Connecticut (398)
Delaware (297)
Europe (116989)
Florida (1355)
Georgia (263)
Hawaii (4)
Idaho (65)
Illinois (671)
India (57)
Indiana (454)
Iowa (21)
Japan (342)
Kansas (133)
Kentucky (32)
Louisiana (16)
Maine (78)
Maryland (1295)
Massachusetts (7414)
Michigan (253)
Minnesota (474)
Mississippi (6)
Missouri (81)
Montana (29)
Nebraska (29)
Nevada (108)
New Hampshire (58)
New Jersey (2602)
New Mexico (30)
New York (2616)
North Carolina (1437)
North Dakota (9)
Northern California (4806)
Ohio (268)
Oklahoma (18)
Oregon (51)
Pennsylvania (1918)
Puerto Rico (22)
Rhode Island (33)
South America (1658)
South Carolina (21)
South Dakota (1)
Southern California (3858)
Tennessee (82)
Texas (1466)
United States (34755)
Utah (223)
Vermont (1)
Virginia (174)
Washington D.C. (55)
Washington State (834)
West Virginia (3)
Wisconsin (87)
859,405 Results for "mirus bio llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
January 16, 2026
·
3 min read
Business
Mirus Bio Named a Top Workplace by the Wisconsin State Journal
Mirus Bio has been named a Top Workplace 2024 by Wisconsin State Journal Top Workplaces.
March 26, 2024
·
2 min read
BioMidwest
Mirus Bio Receives ISO 13485:2016 Certification
Mirus Bio today announced that its quality management system (QMS) has achieved ISO 13485:2016 certification.
January 31, 2024
·
2 min read
BioMidwest
Gamma Biosciences Announces Sale of Mirus Bio to Merck KGaA, Darmstadt, Germany, for $600 Million
Gamma Biosciences announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, whereby Merck KGaA, Darmstadt, Germany, will acquire Gamma operating company Mirus Bio for $600 million in cash.
May 23, 2024
·
4 min read
Deals
MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million.
May 22, 2024
·
4 min read
Press Releases
Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC
June 9, 2025
·
2 min read
Press Releases
MiRus Siegel™ TAVR US Early Feasibility Study (EFS) 30 Day Results Presented at NY Valves Meeting
July 3, 2025
·
3 min read
BioMidwest
Mirus Bio Launches RevIT™ AAV Enhancer
Mirus Bio, a life sciences company developing innovative solutions for nucleic acid delivery to support cell and gene therapy production, biopharmaceutical manufacturing, and research applications, announced the launch of the RevIT AAV Enhancer.
August 3, 2023
·
3 min read
Press Releases
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
February 5, 2026
·
6 min read
Mergers & acquisitions
How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio
Regulatory documents show how 89bio’s board pushed Roche hard for a deal valued at $20 per share in upfront and milestone payments.
October 2, 2025
·
3 min read
·
Annalee Armstrong
1 of 85,941
Next